Management of Diabetic Neuropathy and Balance Problems

Introduction to Treatment Guidelines

The American Diabetes Association recommends optimizing blood glucose control as the first step in managing diabetic neuropathy, targeting HbA1c of 6-7% 3, 4, 2
Good glycemic control delays progression of diabetic neuropathy in type 1 diabetes (Grade A evidence) and slows progression in type 2 diabetes (Grade B/C evidence) 2
Addressing cardiovascular risk factors, including hypertension and dyslipidemia, is crucial as they contribute to neuropathy development 3, 2

Duloxetine (60-120 mg/day) is recommended as first-line pharmacologic therapy for symptomatic relief, with approximately 50% of patients achieving at least 50% pain reduction over 12 weeks, and a NNT of 4.9-5.2 1, 4
Pregabalin (150-600 mg/day) is also recommended, with an NNT of 4.04 for 600 mg/day and 5.99 for 300 mg/day, and is preferred if renal function is normal and there is no depression 1, 2, 5
Gabapentin (900-3600 mg/day) can be considered as an alternative first-line agent, especially if cost is a concern, with a well-established potential cost advantage as a generic 2, 4, 5

Epalrestat (150 mg/day) may be considered as an adjunctive disease-modifying agent to slow neuropathy progression, although it is not approved outside Japan and lacks robust evidence for balance-specific symptoms 1, 2

Optimize glycemic control immediately, targeting HbA1c of 6-7% 3, 2
Rule out other causes of neuropathy, such as vitamin B12 deficiency, hypothyroidism, renal disease, alcohol toxicity, and neurotoxic medications 2
Initiate first-line symptomatic therapy with duloxetine or pregabalin, considering patient-specific factors such as depression and renal function 1, 2

Assess for autonomic neuropathy and screen for orthostatic hypotension, which directly causes imbalance 4, 1, 2
Monitor blood pressure changes when using duloxetine or pregabalin, and consider midodrine or droxidopa if orthostatic hypotension is confirmed 1, 2
Evaluate proprioceptive loss through vibration perception threshold testing and annual 10-g monofilament testing to identify loss of protective sensation 2